Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

A Wellington man is stoked to finally get his hands back on the weight loss drug he said changed his life. Wegovy was approved for weight loss in March 2025 with a doctor’s prescription. The drug ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

As weight loss jabs like Ozempic become ever more popular, doctors are growing increasingly concerned about their gnarly side ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...